Released date: October 17, 2018

InveniAI®’s Innovation Monitoring Platform, AlphaMeld™, Witnesses Rapid Uptake in BioPharma and Adjacencies

InveniAI®’s Innovation Monitoring Platform, AlphaMeld™, Witnesses Rapid Uptake in BioPharma and Adjacencies

Platform built to detect the earliest signs of innovation in real-time and across industries

Branford, CT – October 17, 2018 InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, today announced that since the launch of its AlphaMeld™ platform in early 2018, it has seen rapid adoption and interest not only across BioPharma, but also adjacencies such as Consumer Healthcare, Public Health/Vaccines, and Animal Therapeutics.

InveniAI seeks to make AlphaMeld the go-to platform for all innovative industries. The platform operates in real-time and seamlessly melds human expertise with powerful and optimized machine learning algorithms to identify signals of emerging innovation. With the commercial launch of AlphaMeld™ in Q1 2018, InveniAI has formed partnerships with large Pharma, Specialty Pharma, Biotech, Consumer Healthcare, and has numerous collaborations in advanced negotiations.

Krishnan Nandabalan, Ph.D., President and CEO, InveniAI Corporation said, “Anticipating the future and eliminating uncertainties is critical in shaping business strategy and driving corporate decisions. As we see the digital re-invention of industries, AlphaMeld brings both power and scale to decision-making and plugs a critical gap by engaging both internal experts and machine learning algorithms to identify emerging signals of innovation. Our collaborators are able to make both confident and early decisions using real-time insights specific to their organization’s needs.”

InveniAI continues to push the boundaries of AI and ML in all areas impacting R&D and productivity in BioPharma and is actively exploring adjacencies in other sectors to maximize the application of AlphaMeld. Collaborations are typically multiyear SaaS (Software-as-a-Service) deals.

AlphaMeld™ – Anticipating the Future

AlphaMeld, created on the premise that every innovation begins with a core discovery or invention that gathers momentum, is an artificial intelligence and machine learning based platform that monitors alpha signals indicative of breakthrough innovation. The platform operates in real-time and recognizes these patterns in a rapidly changing and diverse data environment by engaging internal experts to personalize the definition of success and failure for an organization or vertical market. The platform eliminates dependence on a time-series and uses industry-aware scoring algorithms that are customized and further strengthened by incorporating continuous feedback through machine learning.

About InveniAI®

InveniAI, a wholly owned subsidiary of BioXcel Corporation, has pioneered the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across biopharma and other industries. InveniAI is leveraging AI and ML to harness terabytes of disparate data sets to recognize complex patterns and unlock value. InveniAI’s domain expertise spans AI-based innovation monitoring to AI-based drug discovery, already proven with numerous industry collaborations such as Alexion, Centrexion, Takeda, and Axcella among others. We continue to collaborate with our industry partners to address cutting edge problems across the value chain by providing customer-specific solutions that complement both internal and external stakeholder decision-making. We are headquartered in Branford, CT, USA.

Contact Information

Anita Ganjoo, Corporate Communications
T: +1 203 273 8388
E: aganjoo@inveniai.com